FDA nonclinical toxicology review (2023-2024) flagged DNA damage in pituitary cells and injection-site necrosis in animal studies, plus immunogenicity and impurity risks from compounded material, alongside GH/IGF-1-axis effects such as fluid retention, joint discomfort, flushing, and headache reported by users
Save Dihexa is an angiotensin-IV-derived oligopeptide marketed as a research nootropic, and its honest safety picture starts with an absence: there are no published human clinical trials of Dihexa, and therefore no human safety, toxicology, or pharmacokinetic data of any kind
This can be in-person or telehealth depending on the clinic
BPC-157 affects hemostasis in complex ways, reducing both thrombosis risk and bleeding complications in animal studies
However, some of the population is at risk for a vitamin D deficiency, and can supplement this with vitamin D pills